Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2840083 | 0.86 | MAPT (0.54) | MAPTPKMTDP1KMT2AMEN1 | |
| SCHEMBL257010 | 0.86 | ALDH1A1 (0.38) | MAPTPKMSMN1; SMN2TDP1RAB9A | |
| SCHEMBL56358 | 0.80 | MAPT (0.50) | MAPTPKMTDP1KMT2AMEN1 | |
| SCHEMBL2459982 | 0.80 | MAPT (0.35) | MAPTPKMSMN1; SMN2TDP1RAB9A | |
| SCHEMBL9465187 | 0.80 | PKM (0.44) | MAPTPKMSMN1; SMN2HTTLMNA | |
| SCHEMBL29978776 | 0.80 | MAPT (0.35) | MAPTPKMSMN1; SMN2TDP1RAB9A | |
| SCHEMBL6698344 | 0.77 | MAPT (0.48) | MAPTPKMSMN1; SMN2TDP1KMT2A | |
| SCHEMBL9202861 | 0.76 | PKM (0.44) | MAPTPKMSMN1; SMN2TDP1RAB9A | |
| SCHEMBL8873122 | 0.76 | PKM (0.41) | MAPTPKMSMN1; SMN2TDP1RAB9A | |
| SCHEMBL6355485 | 0.74 | PKM (0.43) | MAPTPKMSMN1; SMN2TDP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3450433-B1 | PURINE DERIVATIVES AS TLR7 INHIBITORS FOR TREATING E.G. SYSTEMIC LUPUS ERYTHEMATOSUS | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2021-08-18 | — | — | EP | disclosed |
| US-10703755-B2 | Substituted purine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-07 | — | — | US | disclosed |
| US-10703755-B2 | Substituted purine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-07 | — | — | US | disclosed |
| US-20190169191-A1 | SUBSTITUTED PURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-06-06 | — | — | US | disclosed |
| US-20190169191-A1 | SUBSTITUTED PURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-06-06 | — | — | US | disclosed |
| US-9993476-B2 | Substituted 5-flouro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2018-06-12 | — | — | US | disclosed |
| EP-2542552-B1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-15 | — | — | EP | disclosed |
| WO-2017188287-A1 | SUBSTITUTED PURINE DERIVATIVE | 大日本住友製薬株式会社 | 2017-11-02 | — | — | WO | disclosed |
| US-20170273977-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | ADVERIO PHARMA GMBH (DE) | 2017-09-28 | — | — | US | disclosed |
| US-9718820-B2 | Substituted aza-bicyclic imidazole derivatives useful TRPM8 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-01 | — | — | US | disclosed |
| US-7470696-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1937653-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H.Lundbeck A/S (DK) | 2008-07-02 | — | — | EP | disclosed |
| EP-1581539-A4 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20070135443-A1 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007065449-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H. LUNDBECK A/S (DK) | 2007-06-14 | — | — | WO | disclosed |
| US-20070066612-A1 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2007-03-22 | — | — | US | disclosed |
| US-7189716-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1581539-A2 | NOVEL TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040180897-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| WO-2004063151-A2 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273977-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | PFKP, PON1, FABP3 | MAPT 4407/4885PKM 316/4885SMN1; SMN2 2262/4885 |
| US-20070066612-A1 | Substituted pyrimidine derivatives | DPYD, TYMP, TYMS | MAPT 3682/4885PKM 2298/4885SMN1; SMN2 2572/4885 |
| US-20040180897-A1 | Novel tyrosine kinase inhibitors | ABL1, ROS1, YES1 | MAPT 4438/4885PKM 986/4885SMN1; SMN2 4504/4885 |
| US-10703755-B2 | Substituted purine derivative | TLR7, TLR9, TLR1 | MAPT 4826/4885PKM 4636/4885SMN1; SMN2 967/4885 |
| US-20190169191-A1 | SUBSTITUTED PURINE DERIVATIVE | TLR7, TLR9, TLR1 | MAPT 4826/4885PKM 4636/4885SMN1; SMN2 967/4885 |
| US-20070135443-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, ERBB2, ROS1 | MAPT 4233/4885PKM 954/4885SMN1; SMN2 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.